We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 128

Federal Court holds PM(NOC) findings not necessarily irrelevant in subsequent patent actions VIAGRA (sildenafil citrate)

  • Norton Rose Fulbright Canada LLP
  • -
  • Canada
  • -
  • June 16 2010

On June 11, 2010, Prothonotary Aalto of the Federal Court dismissed a motion by Apotex seeking to strike allegations of res judicata, issue estoppel, collateral estoppel, comity and abuse of process (the “Abuse Allegations”) from Pfizer’s Statement of Defence in an impeachment action

New Canadian trade-mark opposition practice

  • Norton Rose Fulbright Canada LLP
  • -
  • Canada
  • -
  • March 27 2009

On March 31, 2009, Canadian trade-mark opposition practice will again change when a new Practice Notice issued by the Trade-marks Opposition Board comes into force

The proposed UK “Patent Box” legislation - a new 10 per cent rate of corporation tax in the UK

  • Norton Rose Fulbright LLP
  • -
  • United Kingdom
  • -
  • February 3 2010

The 2009 Budget announced that the UK Government would consider changes to the way the tax system encourages innovative activity and the relative attractiveness to global firms as they make decisions on where to locate their research and development and other innovation activities

Substantial changes to the accounting principles of self-created intellectual property in Germany

  • Norton Rose Fulbright LLP
  • -
  • Germany
  • -
  • February 3 2010

The credit crisis has led to substantial liquidity problems especially for medium-sized companies (not only) in Germany: their (almost traditionally) small equity base makes it difficult for them to gain access to fresh money, be it from banks following Basel II regulations, from the capital markets or from private investors

Federal Court of Canada upholds data protection regulations

  • Norton Rose Fulbright Canada LLP
  • -
  • Canada
  • -
  • July 22 2009

On July 17, 2009, Mandamin J. of the Federal Court of Canada (the "Court") dismissed the judicial review applications of the Canadian Generic Pharmaceutical Association and Apotex Inc. and upheld the constitutional validity of section C.08.004.1 of the Food and Drug Regulations, as enacted in 2006 (the "Data Protection Regulations"

Federal Court of Appeal reconfirms that once an NOC issues, a patent holder’s appeal is moot

  • Norton Rose Fulbright Canada LLP
  • -
  • Canada
  • -
  • November 19 2007

On November 5, 2007, a majority of the Federal Court of Appeal granted a motion brought by Novopharm Limited (“Novopharm”) dismissing an appeal brought by Eli Lilly Canada Inc. (“Eli Lilly”) as moot

Federal Court finds Norvasc patent to be invalid

  • Norton Rose Fulbright Canada LLP
  • -
  • Canada
  • -
  • August 26 2009

On July 8, 2009, the Federal Court (Hughes J) granted ratiopharm inc. a declaration under section 60(1) of the Patent Act (the "Act") that Canadian Patent No. 1,321,393 (the "’393 Patent") is invalid

Rambus commitments accepted by Commission in final settlement

  • Norton Rose Fulbright LLP
  • -
  • European Union
  • -
  • February 2 2010

Having offered commitments to the Commission in an attempt to end the investigation into an alleged abuse of dominance in the form of a "patent ambush", Rambus announced in December that these commitments had been accepted by the Commission

Pharma in brief - Canada: Merck awarded substantial damages for infringement of lovastatin patent

  • Norton Rose Fulbright LLP
  • -
  • Canada
  • -
  • July 31 2013

The Federal Court held that Merck and Co., Inc. (“Merck US”) and Merck Canada Inc. (“Merck Canada”) (collectively “Merck”) are entitled to $119,054

Federal Court denies prohibition order patents not infringed - desloratidine (Aerius)

  • Norton Rose Fulbright Canada LLP
  • -
  • Canada
  • -
  • January 26 2010

On December 22, 2009, the Federal Court dismissed an application for an Order preventing the Minister of Health from issuing a notice of compliance to Pharmascience Inc. ("PMS") in respect of a generic version of Schering-Plough’s ("Schering") desloratidine drug until the expiry of Canadian Patent Nos. 2,325,014 ("'014 patent") and 2,267,136 ("'136 patent"